WAUKEGAN, Ill.--(BUSINESS WIRE)--Aug. 7, 2006--NEOPHARM, Inc. (Nasdaq:NEOL - News) today announced progress in the Company’s reimbursement position for CINTREDEKIN BESUDOTOX (IL13-PE38QQR), which is being studied for the treatment of glioblastoma multiforme at first recurrence, the most common type of malignant primary brain tumor in adults. The American Medical Association (AMA) and the Centers for Medicare and Medicaid Services (CMS) have assigned unique CPT and ICD-9 procedure codes, respectively, for Convection Enhanced Delivery (CED) catheter implantation, a novel drug delivery technique used to administer CINTREDEKIN BESUDOTOX directly into the brain. The CPT and ICD-9 procedure coding systems are designed to define and describe medical procedures performed by physicians and other health providers and are expected to be of importance in securing appropriate reimbursement for the potential CINTREDEKIN BESUDOTOX treatment regimen.
